Ataluren/ivacaftor combination therapy: Two N‐of‐1 trials in cystic fibrosis patients with nonsense mutations
- 13 April 2020
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (7), 1838-1842
- https://doi.org/10.1002/ppul.24764
Abstract
Premature termination codons (PTCs) in cystic fibrosis transmembrane conductance regulator (CFTR) produce nonfunctional protein. No approved therapies exist for PTC mutations, including W1282X. We hypothesized that ivacaftor, combined with readthrough therapy, may benefit W1282X patients. Two N-of-1 clinical trials were conducted with ataluren and ivacaftor in various combinations. No meaningful clinical benefit was observed in either patient with ivacaftor alone or ataluren/ivacaftor combination. However, isolated improvements of uncertain significance were noted by a nasal potential difference (NPD) and FEV1% with ivacaftor in Patient-1 and with ataluren/ivacaftor combination by NPD and body mass index in Patient-2. Drug regimen composed of readthrough agents and potentiators warrant further development for W1282X and other CFTR nonsense mutations.Keywords
Funding Information
- Cystic Fibrosis Foundation (Steven Rowe)
This publication has 6 references indexed in Scilit:
- Decreased mRNA and protein stability of W1282X limits response to modulator therapyJournal of Cystic Fibrosis, 2019
- Ataluren in cystic fibrosis: development, clinical studies and where are we now?Expert Opinion on Pharmacotherapy, 2017
- Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense MutationsAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutationJournal of Cystic Fibrosis, 2016
- Restoration of W1282X CFTR Activity by Enhanced ExpressionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosisCell, 1993